Credit Industriel ET Commercial Takes $4.54 Million Position in Grifols, S.A. (NASDAQ:GRFS)

Credit Industriel ET Commercial bought a new position in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 609,855 shares of the biotechnology company's stock, valued at approximately $4,537,000. Grifols makes up approximately 0.6% of Credit Industriel ET Commercial's portfolio, making the stock its 22nd largest position. Credit Industriel ET Commercial owned 0.09% of Grifols at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Capital World Investors raised its position in shares of Grifols by 0.7% during the 4th quarter. Capital World Investors now owns 21,134,230 shares of the biotechnology company's stock worth $157,239,000 after acquiring an additional 154,358 shares in the last quarter. Brandes Investment Partners LP grew its stake in Grifols by 3.0% during the 4th quarter. Brandes Investment Partners LP now owns 20,496,093 shares of the biotechnology company's stock worth $152,491,000 after buying an additional 592,096 shares during the last quarter. Black Creek Investment Management Inc. grew its stake in Grifols by 1.3% during the 4th quarter. Black Creek Investment Management Inc. now owns 11,251,960 shares of the biotechnology company's stock worth $83,715,000 after buying an additional 141,615 shares during the last quarter. Norges Bank purchased a new position in Grifols during the 4th quarter worth approximately $14,434,000. Finally, Highland Peak Capital LLC grew its stake in Grifols by 29.5% during the 4th quarter. Highland Peak Capital LLC now owns 786,210 shares of the biotechnology company's stock worth $5,849,000 after buying an additional 179,114 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Morgan Stanley assumed coverage on Grifols in a research note on Wednesday, February 12th. They set an "overweight" rating on the stock. Wall Street Zen upgraded Grifols from a "hold" rating to a "buy" rating in a research note on Friday, May 23rd.

Grifols Stock Performance

NASDAQ:GRFS traded up $0.18 during mid-day trading on Thursday, reaching $8.36. 656,288 shares of the stock were exchanged, compared to its average volume of 1,158,782. The company has a 50 day simple moving average of $7.33 and a 200-day simple moving average of $7.58. The stock has a market capitalization of $5.75 billion, a P/E ratio of 7.15 and a beta of 0.44. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. Grifols, S.A. has a 1 year low of $5.79 and a 1 year high of $9.96.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.